Overview

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Rifampin